Drug intelligence / Profile preview

VLX-2000

Development stage: Preclinical
Lead developer: Veralox Therapeutics
Modality: Small Molecules

Overview

**VLX-2000** is a small-molecule inhibitor of ALOX12 (12-lipoxygenase, or 12-LOX), an enzyme involved in immune-mediated inflammatory pathways. Developed by Veralox Therapeutics for IgG-mediated and autoimmune diseases, it targets platelet activation and inflammation downstream of 12-LOX. It is a follow-on compound to VLX-1005 and is currently in preclinical development.

Beyond the preview

Go deeper on VLX-2000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VLX-2000.

Explore the full profile